Table III.
The incidence of various adverse outcomes data of patients in each experimental group.
| Variables | Saline+GA (n=23) | Ketamine+GA (n=17) | Bupivacaine+GA (n=16) | Ket+bupi+GA (n=16) |
|---|---|---|---|---|
| Sedation | 6 (26.00)a | 3 (17.00) | 3 (18.70) | 1 (6.25) |
| Sweating | 1 (4.30)a | 1 (5.88) | 0 | 0 |
| Constipation | 3 (13.00)a | 0 | 1 (6.25) | 0 |
| Dizziness | 4 (17.30)a | 3 (17.00)c | 2 (12.50) | 1 (6.25) |
| Urinary retention | 4 (17.30)b | 3 (17.00)c | 2 (12.50) | 1 (6.25) |
| PONV | 7 (30.40)b | 4 (23.50)c | 4 (25.00)d | 2 (12.50) |
Data are presented as numbers of patients (%).
a
P<0.05
b
P<0.01 vs. saline+GA
c
P<0.05 vs. ketamine+GA
d
P<0.05 vs. bupivacaine+GA. GA, general anesthesia; ket+bupi, ketamine and bupivacaine; PONV, post-operative nausea and vomiting.